Asieris Pharmaceuticals is a biotech company focusing on therapeutic areas in oncology and multidrug-resistant infections.
Asieris Pharma specializes in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases.
Asieris Pharma was founded in 2010 by Kevin Pan and Zhuang Chengfeng. The company has set up divisions in Beijing and the US and an R&D centre in Shanghai.
Asieris Pharmaceuticals is dedicated to becoming the most innovative, influential, respectable, and reliable pharmaceutical company in our areas of focus.
Asieris Pharma's goal is to establish a leading position in this field with our own unique strategies. Through the "twin engines" of proprietary R&D and in-licensing, it explores the global values of proprietary first-in-class new drugs of breakthrough potential.
Asieris Pharma is backed by TF Capital, Yanyuan Innovation Capital, Shenzhen Guozhong Venture Capital Management, Lapam Capital, Kaitai Capital and others. The company raised $14M in a Series C round on Mar 24, 2020. This brings Asieris' total funding to $28M to date.